• Skip to primary navigation
  • Skip to main content
English Spainish
My Account
LaRed Home

LaRed

Mexican Emerging Infectious Disease Clinical Research Network

  • About Us
    • About Us
    • Leadership
    • Partners
  • Studies
    • ACTT
    • CN-SARI
    • FLU-IVIG
    • FLU-PRO
    • HEALTHY COHORT
    • INSIGHT-011
    • ILI 2014
    • ILI 002
    • IRC 003
    • NTZ-SARI
    • SPRINT-SARI
    • ZIK 01
    • InVITE
    • OTAC
  • News and Events
  • Resources
    • Publications
    • Regulations / Policies
  • Contact Us
    • Contact Us
    • Sites

INSIGHT-012_OTAC

Treatment of outpatients with anti-Coronavirus immunoglobulin (INSIGHT-012_OTAC)

November 7, 2022 by

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trials of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19 (INSIGHT-012_OTAC)

This study will evaluate a treatment strategy for COVID-19 patients with passive immunotherapy plus current standard of care treatment. The goal is to find out if the study drug is safe, and if it will help people stay out of the hospital and have fewer problems caused by COVID-19.

Tagged With: COVID-19, INSIGHT-012, OTAC

Footer Logo

The Mexican Emerging Infectious Disease Clinical Research Network (LaRed)

Address:
Coscomate 71, Int. 1A, Colonia Toriello Guerra, Alcaldía Tlalpan, CP 14050 CdMx
Phone:
(+52) 55 5573 0734, (+52) 55 5162 5552

Main Navigation


  • Home
  • About
  • Studies
  • News & Events
  • Resources
  • Contact

Site Help


  • Sitemap
  • Privacy
  • Terms Of Use
Copyright ©2019 All rights reserved | LaRed

Multilingual WordPress with WPML